Indications, usage and dosage described in the instructions for brigatinib

Brigatinib, trade name Alunbrig, is an oral targeted anti-cancer drug and a second-generation anaplastic lymphoma kinase (ALK) inhibitor. The drug is mainly used to treat patients with non-small cell lung cancer (NSCLC) who carry ALK gene fusions or rearrangements. It is especially suitable for patients who are resistant or intolerant to first-generation ALK inhibitors such as crizotinib (Crizotinib). The development and marketing of brigatinib provides a new treatment option for patients with ALK positive lung cancer, effectively prolonging the patients' progression-free survival (PFS) and overall survival (OS). The following will introduce in detail the indications, usage and dosage recommended in the instructions for brigatinib.

1. Indications

According to the latest drug instructions and State Food and Drug Administration approval information, brigatinib is suitable for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. This includes treatment-naïve patients as well as patients who have developed resistance or disease progression to first-generation ALK inhibitors such as crizotinib. Brigatinib's highly selective inhibition of the ALK fusion gene can effectively block the growth and spread of tumor cells and significantly improve the treatment prognosis of patients. In addition, brigatinib also shows good efficacy in the treatment of patients with brain metastases and has the ability to penetrate the blood-brain barrier.

2. Usage and dosage

Brigatinib is in oral capsule form and is easy to take. Treatment usually starts at a lower dose and is titrated according to the dosing regimen recommended in the labeling to reduce the risk of early pulmonary side effects. The specific medication regimen is: take 90 mg once daily from the 1 to 7 days of treatment. , starting from the 8th day, the dose is increased to 180 mg twice a day, and this dose is maintained until the disease progresses or intolerable side effects occur.

Patients should take oral brigatinib at the same time every day. The drug can be taken with food or on an empty stomach. The drug should be taken with plenty of water. During treatment, if serious adverse reactions occur, the doctor may adjust the dose according to the patient's tolerance and temporarily stop or reduce the dose if necessary. It is recommended that patients return for regular follow-up visits, conduct regular monitoring of liver and kidney function, electrolytes and heart function, and promptly detect and deal with potential adverse reactions.

3. Special medication precautions

The instructions specifically emphasize that brigatinib may cause pulmonary toxicity, especially in the early stages of treatment, manifesting as symptoms such as pneumonia and interstitial lung disease. If patients have difficulty breathing, cough or fever, they should seek medical treatment immediately. The doctor will decide whether to suspend the medication and take corresponding treatment based on the specific situation. In addition, brigatinib may cause hypertension, arrhythmia, abnormal liver function, etc., and blood pressure and electrocardiogram changes need to be closely monitored.

In addition, brigatinib has a certain impact on the QT interval, so caution should be used when combining drugs that may prolong the QT interval. Patients should inform their doctors about all medications they are taking to avoid potential drug interactions. Pregnant women, lactating women and patients with severe liver and kidney dysfunction should use it with extreme caution.

Brigatinib, as a second-generation ALK inhibitor, has become an important treatment option for patients with ALK-positive non-small cell lung cancer due to its efficient anti-tumor activity and good ability to control brain metastasis. The instructions clearly recommend a dosage regimen starting from 90 mg and gradually increasing to 180 mg to balance efficacy and safety. Patients need to closely cooperate with their doctors during medication, pay attention to potential side effects, and conduct relevant examinations regularly to ensure safe and effective treatment. By standardizing the use of brigatinib, patients' survival can be maximized and their quality of life can be improved.

Reference materials:https://www.drugs.com